NASDAQ:ONCE - Spark Therapeutics Stock Price, News, & Analysis

$101.95
+2.26 (+2.27 %)
(As of 06/19/2019 07:18 AM ET)
Today's Range
$98.21
Now: $101.95
$102.17
50-Day Range
$97.70
MA: $107.23
$111.18
52-Week Range
$34.53
Now: $101.95
$114.20
Volume978,258 shs
Average Volume608,386 shs
Market Capitalization$3.92 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCE
CUSIPN/A
Phone888-772-7560

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.72 million
Book Value$13.15 per share

Profitability

Net Income$-78,820,000.00
Net Margins-124.33%

Miscellaneous

Employees368
Market Cap$3.92 billion
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable

Receive ONCE News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.

Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) released its earnings results on Friday, May, 10th. The biotechnology company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by $0.33. The biotechnology company had revenue of $20.77 million for the quarter, compared to the consensus estimate of $31.20 million. Spark Therapeutics had a negative return on equity of 16.68% and a negative net margin of 124.33%. View Spark Therapeutics' Earnings History.

When is Spark Therapeutics' next earnings date?

Spark Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Spark Therapeutics.

What price target have analysts set for ONCE?

20 analysts have issued 1 year price targets for Spark Therapeutics' stock. Their forecasts range from $40.00 to $115.00. On average, they anticipate Spark Therapeutics' stock price to reach $79.8044 in the next year. This suggests that the stock has a possible downside of 21.7%. View Analyst Price Targets for Spark Therapeutics.

What is the consensus analysts' recommendation for Spark Therapeutics?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 17 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Spark Therapeutics.

What are Wall Street analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:
  • 1. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (5/25/2019)
  • 2. William Blair analysts commented, "We see a sound strategic fit with Roche given its recent investment in hemophilia with the launch of Hemlibra (SPK-8011 in hemophilia A, SPK-8016 in hemophilia A patients with inhibitors and royalties from the fidanacogene elaparvovec collaboration with Pfizer), ophthalmology (Luxturna in the United States and royalties from the Luxturna EU launch), and neuroscience (SPK-1001 for CLN2) franchises." (2/26/2019)
  • 3. JPMorgan Chase & Co. analysts commented, "ONCE’s 3Q print encouragingly showed in line Luxturna sales of ~$9M, although a resetting of expectations around the SPK-8011 update at ASH overshadowed launch progress. Given the historical focus on FVIII levels, we aren’t surprised to see disappointment about the news that there will be no biomarker data for the high dose cohort at ASH (there will be clinical outcome data). Indeed, for some time we’ve gotten the sense that at least some investors may wait to see additional SPK-8011 FVIII activity data before re-engaging. That said, today’s update doesn’t fundamentally change the fact that ONCE continues to be a leader in the gene therapy space, with an active early-stage pipeline (2 new programs entering clinic in late- 2018/2019) and an update on SPK-7001 expected by YE18. Maintain Neutral." (11/7/2018)

Has Spark Therapeutics been receiving favorable news coverage?

News headlines about ONCE stock have been trending somewhat positive this week, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Spark Therapeutics earned a coverage optimism score of 1.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Spark Therapeutics.

Who are some of Spark Therapeutics' key competitors?

What other stocks do shareholders of Spark Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Gilead Sciences (GILD), NVIDIA (NVDA), Exelixis (EXEL), Alibaba Group (BABA), Celgene (CELG), AbbVie (ABBV), Micron Technology (MU), BioMarin Pharmaceutical (BMRN) and Sangamo Therapeutics (SGMO).

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 40)
  • Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 67)
  • Mr. Stephen W. Webster, Chief Financial Officer (Age 58)
  • Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 48)
  • Mr. Daniel R. Faga, Chief Bus. Officer (Age 39)

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Who are Spark Therapeutics' major shareholders?

Spark Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.60%), CNH Partners LLC (2.04%), Alpine Associates Management Inc. (1.79%), IndexIQ Advisors LLC (1.72%), Gabelli Funds LLC (1.56%) and Syquant Capital Sas (1.47%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.

Which institutional investors are selling Spark Therapeutics stock?

ONCE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., DekaBank Deutsche Girozentrale, New York State Common Retirement Fund, Pinnacle Associates Ltd., FIL Ltd, C WorldWide Group Holding A S and Bailard Inc.. View Insider Buying and Selling for Spark Therapeutics.

Which institutional investors are buying Spark Therapeutics stock?

ONCE stock was acquired by a variety of institutional investors in the last quarter, including CNH Partners LLC, Alpine Associates Management Inc., IndexIQ Advisors LLC, Gabelli Funds LLC, Syquant Capital Sas, SG Americas Securities LLC, FNY Investment Advisers LLC and GABELLI & Co INVESTMENT ADVISERS INC.. View Insider Buying and Selling for Spark Therapeutics.

How do I buy shares of Spark Therapeutics?

Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of ONCE stock can currently be purchased for approximately $101.95.

How big of a company is Spark Therapeutics?

Spark Therapeutics has a market capitalization of $3.92 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Spark Therapeutics employs 368 workers across the globe.View Additional Information About Spark Therapeutics.

What is Spark Therapeutics' official website?

The official website for Spark Therapeutics is http://www.sparktx.com/.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]


MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  470 (Vote Outperform)
Underperform Votes:  387 (Vote Underperform)
Total Votes:  857
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel